Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Transgene (0OCQ) Share Price & Analysis

0OCQ Stock Chart & Stats

€0.72€0.01(1.69%)
At close: 4:30 PM GMT
EUR 0.7EUR 0.8EUR 0.94 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
EUR 0.72 - EUR 0.73
52-Week Range
EUR 0.68 - EUR 1.50
Previous Close
EUR 0.71
Volume
384
Average Volume (3M)
901
Market Cap
EUR 202.03M
Enterprise Value
EUR 108.26M
Total Cash (Recent Filing)
EUR 92.84M
Total Debt (Recent Filing)
EUR 2.18M
Price to Earnings (P/E)
―
Beta
0.21
Next Earnings
Nov 09, 2026 (Est.)
EPS Estimate
N/A
Last Dividend Ex-Date
Mar 15, 2022
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage And Substantial Equity Base

Very low leverage provides Transgene with greater financial flexibility than a heavily indebted biotech and limits near-term balance-sheet pressure. The sizable equity base can help support continued development activity, although its effectiveness depends on the company’s ability to control ongoing losses and cash usage.

Focused Oncology Immunotherapy Platform

Transgene’s concentration on oncology immunotherapies gives it a coherent scientific strategy across multiple solid-tumor programs. Viral-vector and individualized vaccine capabilities may support differentiated development opportunities and combination use, creating potential platform value beyond a single clinical candidate.

Year-over-year Free Cash Flow Improvement

The improvement in free cash flow versus the prior year is a constructive operational signal, suggesting that cash consumption may be moderating from the previous period. If sustained, better cash control could extend the development runway and reduce the pace at which additional financing is required.

Bears Say

Persistent Losses And Deeply Negative Margins

Persistent losses and severely negative margins show that the current cost base is not supported by revenue, leaving profitability dependent on future clinical or commercial progress. Without sustained revenue growth or cost reduction, negative earnings can continue to consume capital and weaken shareholder returns.

Severe Revenue Deterioration And Volatility

The sharp revenue decline and historical volatility indicate that Transgene lacks a stable near-term revenue foundation. This makes financial planning more difficult, increases dependence on pipeline milestones for future value creation, and limits the company’s ability to fund research and development internally.

Ongoing Cash Burn And External Funding Dependence

Continued negative operating and free cash flow means Transgene is consuming cash rather than funding development from operations. Reliance on external financing can constrain strategic flexibility and may create recurring funding or dilution pressure while the pipeline remains in development.

Transgene News

0OCQ FAQ

What was Transgene’s price range in the past 12 months?
Transgene lowest share price was €0.68 and its highest was €1.50 in the past 12 months.
What is Transgene’s market cap?
Transgene’s market cap is €202.03M.
When is Transgene’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Transgene’s earnings last quarter?
Transgene released its earnings results on Sep 24, 2026. The company reported -€0.057 earnings per share for the quarter.
Is Transgene overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Transgene pay dividends?
Transgene pays a Notavailable dividend of €0.285 which represents an annual dividend yield of ―. See more information on Transgene dividends here
What is Transgene’s EPS estimate?
Transgene’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Transgene have?
Transgene has 278,559,940 shares outstanding.
What happened to Transgene’s price movement after its last earnings report?
Transgene reported an EPS of -€0.057 in its last earnings report. Following the earnings report the stock price went down -5.14%.
Which hedge fund is a major shareholder of Transgene?
Currently, no hedge funds are holding shares in GB:0OCQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology